Guillain Barré syndrome—Incidence and clinical course in Southern Rogaland, Norway

Guillain-Barré syndrome is an orphan autoimmune disease associated with the involvement of the peripheral nervous system. The clinical course of the syndrome has four main types. We present a clinical case of Guillain-Barré syndrome in a 6-year old child. Against the background of a previous infection, he developed oculomotor dysfunction, peripheral tetraparesis, sensory abnormalities with subsequent severe weakness of the respiratory muscles. The differential diagnosis included inflammatory, infectious and neoplastic spinal cord disorders, spinal cord magnetic resonance imaging, and examination of the cerebrospinal fluid. The patient's electromyographic data confirmed peripheral nerve damage. Based on all of these, the patient was diagnosed with Guillain-Barré syndrome. Specific treatment, including plasmapheresis and intravenous human immunoglobulin G at a dose of 0.4 mg daily for 5 days, and symptomatic treatment resulted in gradual improvement and complete regression of the neurological symptoms completely resolved. Since Guillain-Barré syndrome is a rare disease of the peripheral nervous system, the awareness of the specifics of its clinical course allows for earlier correct diagnosis and effective treatment.

Download Full-text

A Systematic Review on Immunotherapy for Guillain- Barre Syndrome

Journal of Bangladesh College of Physicians and Surgeons ◽

10.3329/jbcps.v40i1.57060 ◽

2022 ◽

Vol 40 (1) ◽

pp. 57-64

Author(s):

Abu Nayeem ◽

Quazi Deen Mohammad ◽

Zobaida Sultana Susan

Keyword(s):

Low Income ◽

Clinical Course ◽

Guillain Barre Syndrome ◽

Low Income Countries ◽

Outcome Study ◽

Access To Treatment ◽

Geographical Variations ◽

Disease Modifying Therapies ◽

Guillain Barré Syndrome ◽

Guillain Barré

Guillain-Barré syndrome (GBS) is an acute immunemediated polyradiculoneuropathy with a highly variable clinical course and outcome. Intravenous immunoglobulin (IVIG) and plasma exchange (PE) are proven effective treatments, but about half of the patients may not respond to these therapies; moreover, these are not established yet to treat patients of every stage of GBS or its variants. Results from the International Guillain-Barré Syndrome Outcome Study suggest that geographical variations exist in Guillain-Barré syndrome, including insufficient access to immunotherapy in low-income countries. There is a need to provide improved access to treatment for all patients with Guillain-Barré syndrome, and to develop effective disease-modifying therapies that can limit the extent of nerve injury. In this review, the current literature about immunotherapeutic options is highlighted in the context of stages of the disease and its variants and additionally, upcoming modalities are discussed briefly. J Bangladesh Coll Phys Surg 2022; 40: 57-64

Download Full-text

Comparison of Clinical and Biochemical Parameters of Patients with Guillain Barre Syndrome and Myasthenia Gravis: Retrospective Single Center Experience

Journal of Research in Clinical Medicine ◽

10.34172/jrcm.2021.007 ◽

2021 ◽

Vol 9 (1) ◽

pp. 7-7

Author(s):

Mehmet Nuri Kocak ◽

Erdal Tekin ◽

Mustafa Bayraktar

Keyword(s):

Clinical Course ◽

Binding Capacity ◽

Guillain Barre Syndrome ◽

Laboratory Findings ◽

Single Center Experience ◽

Respiratory Involvement ◽

Guillain Barré Syndrome ◽

Neurological Autoimmune Diseases ◽

Guillain Barré ◽

Iron Binding Capacity

Background: Guillain-Barré syndrome (GBS) and Miyastenia gravis (MG) are common neurological autoimmune diseases. With this study, we aimed to compare the patients’ complaints, clinical course and laboratory parameters of both diseases. Methods: This study was carried out as a retrospective file scan. The study covers the dates between April 1, 2017, and April 20, 2020. The GBS and MG patients were compared in terms of sociodemographic characteristics, application complaints, clinical course, laboratory findings, treatments and outcomes. Results: In this study, 51 patients from both groups were included. The mean age of GBS and MG patients was 52.1 ±19.4 and 43.6 ±15.8 years, respectively. Respiratory involvement of the patients was 23.5% in GBS and 17.6% in MG. When the treatments of the patients were compared, it was observed that 78.4% of GBS patients and 98% of MG received IVIG treatments. Only two patients from GBS group were found to be ex. When the laboratory results were compared, it was found that lactate, vitamin D, transferrin and total iron binding capacity results were lower in GBS patients, whereas, vitamin B12 and ferritin results were lower in MG patients and this difference was statistically significant (p <0.05). Conclusion: The clinical presentation of GBS and MG is diverse and the prognosis can vary significantly among patients. Within the scope of the data obtained from the study, it was concluded that wide anamnesis and laboratory analyzes are necessary and useful for the differential diagnosis of these two diseases.

Download Full-text